7,269 Shares in Illumina, Inc. (NASDAQ:ILMN) Purchased by Quantessence Capital LLC

Quantessence Capital LLC acquired a new stake in Illumina, Inc. (NASDAQ:ILMN - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 7,269 shares of the life sciences company's stock, valued at approximately $971,000.

Several other large investors also recently modified their holdings of the company. Golden State Wealth Management LLC bought a new stake in Illumina during the fourth quarter valued at $32,000. Versant Capital Management Inc boosted its position in shares of Illumina by 153.7% during the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company's stock valued at $32,000 after purchasing an additional 146 shares in the last quarter. Bank Julius Baer & Co. Ltd Zurich acquired a new stake in Illumina during the fourth quarter worth approximately $45,000. Assetmark Inc. grew its stake in Illumina by 954.8% during the fourth quarter. Assetmark Inc. now owns 327 shares of the life sciences company's stock worth $44,000 after purchasing an additional 296 shares during the period. Finally, Lee Danner & Bass Inc. bought a new stake in Illumina in the fourth quarter worth approximately $48,000. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts have recently commented on the stock. TD Cowen downgraded shares of Illumina from a "buy" rating to a "hold" rating and reduced their price objective for the stock from $177.00 to $140.00 in a research report on Friday, February 7th. Guggenheim cut their price objective on shares of Illumina from $170.00 to $150.00 and set a "buy" rating on the stock in a research report on Friday, February 7th. Barclays decreased their target price on Illumina from $100.00 to $77.00 and set an "underweight" rating for the company in a research report on Thursday, April 10th. Morgan Stanley reduced their price objective on Illumina from $150.00 to $136.00 and set an "equal weight" rating for the company in a research note on Tuesday, February 11th. Finally, Robert W. Baird cut their target price on Illumina from $127.00 to $90.00 and set a "neutral" rating on the stock in a report on Wednesday, March 5th. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Illumina presently has a consensus rating of "Moderate Buy" and a consensus price target of $138.70.

Illumina Stock Performance

ILMN traded down $0.26 on Friday, hitting $77.35. The company's stock had a trading volume of 1,424,483 shares, compared to its average volume of 2,286,599. Illumina, Inc. has a 12 month low of $68.70 and a 12 month high of $156.66. The firm has a market cap of $12.24 billion, a P/E ratio of -10.07, a price-to-earnings-growth ratio of 1.60 and a beta of 1.38. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63. The company's 50 day simple moving average is $82.02 and its 200-day simple moving average is $118.05.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing analysts' consensus estimates of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. Analysts forecast that Illumina, Inc. will post 4.51 EPS for the current year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.